Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Mönch S, Heimer MM, Winkelmann M, Guertler A, Schlaak M, Tufman A, Ben Khaled N, de Toni E, Westphalen CB, von Bergwelt-Baildon M, Dinkel J, Kazmierczak PM, Ingrisch M, Mansour N, Unterrainer M, Heinzerling L, Ricke J, Kunz WG. Mönch S, et al. Among authors: schlaak m. Cancer Imaging. 2023 Jun 8;23(1):58. doi: 10.1186/s40644-023-00580-9. Cancer Imaging. 2023. PMID: 37291665 Free PMC article.
Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation.
Schlaak M, Kurschat P, Shimabukuro-Vornhagen A, Scheid C, Chemnitz J, Stadler R, von Bergwelt-Baildon M, Theurich S. Schlaak M, et al. Transpl Immunol. 2011 Sep;25(2-3):163-6. doi: 10.1016/j.trim.2011.06.008. Epub 2011 Jul 2. Transpl Immunol. 2011. PMID: 21745569
Mast cells play a protumorigenic role in primary cutaneous lymphoma.
Rabenhorst A, Schlaak M, Heukamp LC, Förster A, Theurich S, von Bergwelt-Baildon M, Büttner R, Kurschat P, Mauch C, Roers A, Hartmann K. Rabenhorst A, et al. Among authors: schlaak m. Blood. 2012 Sep 6;120(10):2042-54. doi: 10.1182/blood-2012-03-415638. Epub 2012 Jul 26. Blood. 2012. PMID: 22837530 Free article.
Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.
Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A. Müller P, et al. Among authors: schlaak m. Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198. Epub 2014 Apr 21. Cancer Immunol Res. 2014. PMID: 24916470
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. Müller-Jensen L, et al. Among authors: schlaak m. Data Brief. 2022 Sep 30;45:108649. doi: 10.1016/j.dib.2022.108649. eCollection 2022 Dec. Data Brief. 2022. PMID: 36426082 Free PMC article.
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
Thiem A, Mashhadiakbar P, Cussigh C, Hassel JC, Grimmelmann I, Gutzmer R, Schlaak M, Heppt MV, Dücker P, Hüning S, Schulmeyer L, Schilling B, Haferkamp S, Ziemer M, Moritz RKC, Hagelstein V, Terheyden P, Posch C, Gaiser MR, Kropp P, Emmert S, Müller B, Tietze JK. Thiem A, et al. Among authors: schlaak m. J Eur Acad Dermatol Venereol. 2023 May;37(5):884-893. doi: 10.1111/jdv.18778. Epub 2022 Dec 7. J Eur Acad Dermatol Venereol. 2023. PMID: 36433671
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
Tsakmaklis A, Farowski F, Zenner R, Lesker TR, Strowig T, Schlößer H, Lehmann J, von Bergwelt-Baildon M, Mauch C, Schlaak M, Knuever J, Schweinsberg V, Heinzerling LM, Vehreschild MJGT. Tsakmaklis A, et al. Among authors: schlaak m. BMC Cancer. 2023 Nov 28;23(1):1160. doi: 10.1186/s12885-023-11551-5. BMC Cancer. 2023. PMID: 38017389 Free PMC article.
361 results